The SARS Coronavirus 2 (SARS‐CoV‐2) causing the corona virus disease‐19 (COVID‐19) pandemic has changed the lives of everybody on this planet. As a new disease with an appreciable mortality and no curative treatment, COVID‐19 has stimulated a huge worldwide research effort into every aspect of the virus and the nature of the disease it causes. Health care workers have had to rapidly learn the essentials of the biology, epidemiology, pathophysiology, diagnosis and clinical manifestations of the COVID‐19 virus. Hematologists are now faced every day with the challenge of balancing the proper maintenance of patient care with appropriate precautions to prevent the spread of the virus. Guidelines to manage patients with blood diseases, with or without the virus, during these times are urgently needed.

There has been an unprecedented response of medical communities worldwide to COVID‐19 at local, national and international levels. The World Health Organization has issued new directives to mitigate the effects of the pandemic, one of which is to mandate that all medical and scientific journals make available to them any manuscript dealing with COVID‐19. The BJHaem is glad to do its part in facilitating the rapid dissemination of such critical information. To best serve the international hematological community we will rapidly publish manuscripts that can educate and guide our readers with the latest information on the virus and its disease. To address the new challenge to hematological practice caused by COVID‐19 and to quickly disseminate relevant new findings about the virus and the disease as it relates to hematology the BJHaem is opening a new section in the journal for COVID‐19 management guidelines, case series and research papers.

In this issue we have assembled the first of these COVID‐19 papers. We present guidelines covering the general management of patients with blood diseases and those undergoing stem cell transplantation. We also publish here original papers and letters addressing hematological features of the disease. These submissions coming from Asia, Europe and America represent the first in a steady stream of manuscripts. The BJHaem will continue to publish on COVID‐19 for as long as necessary. Nevertheless we fervently hope that the need for the COVID‐19 section will be brief.
